SOM 0777

Drug Profile

SOM 0777

Alternative Names: JLB 137; SOM 0777

Latest Information Update: 27 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SOM Biotech
  • Class Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 31 Jan 2016 SOM 0777 is available for licensing as of 31 Jan 2016. www.sombiotech.com
  • 31 Jan 2016 Preclinical trials in Glioblastoma in Spain (PO) before January 2016
  • 31 Jul 2013 SOM 0777 licensed to Argon Pharma for the treatment of Glioblastoma (SOM Biotech website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top